Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

[1]  C. Lewis,et al.  Calcium, magnesium and potassium intake and mortality in women with heart failure: the Women's Health Initiative. , 2013, The British journal of nutrition.

[2]  G. Ogedegbe,et al.  Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.

[3]  G. Filippatos,et al.  A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial , 2012, Heart Failure Reviews.

[4]  X. Sui,et al.  Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. , 2009, International Journal of Cardiology.

[5]  D. Leosco,et al.  Hypermagnesemia predicts mortality in elderly with congestive heart disease: relationship with laxative and antacid use. , 2008, Rejuvenation research.

[6]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[7]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[8]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[9]  N. Bachl,et al.  Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients , 2006, British Journal of Sports Medicine.

[10]  D. DeMets,et al.  Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). , 2005, Journal of cardiac failure.

[11]  J. Molnar,et al.  The Effect of Magnesium Sulfate on Action Potential Duration and Cardiac Arrhythmias , 2005, American journal of therapeutics.

[12]  A. Golik,et al.  Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation , 2003, Heart.

[13]  S. Chakraborti,et al.  Protective role of magnesium in cardiovascular diseases: A review , 2002, Molecular and Cellular Biochemistry.

[14]  M. Brodsky,et al.  Significance of magnesium in congestive heart failure. , 1996, American heart journal.

[15]  C. Sueta,et al.  Antiarrhythmic action of pharmacological administration of magnesium in heart failure: a critical review of new data. , 1995, Magnesium research.

[16]  S. Dunlap,et al.  Effect of Acute Magnesium Administration on the Frequency of Ventricular Arrhythmia in Patients With Heart Failure , 1994, Circulation.

[17]  M. Fisher,et al.  Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. , 1993, American heart journal.

[18]  P. Fenster,et al.  Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. , 1993, Journal of the American College of Cardiology.

[19]  M. Fisher,et al.  Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. , 1990, Journal of the American College of Cardiology.

[20]  O. Stepura,et al.  Magnesium orotate in severe congestive heart failure (MACH). , 2009, International journal of cardiology.

[21]  K. Swedberg,et al.  Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure , 2007 .

[22]  K. Kisters,et al.  Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate-induced hypertension in rats. , 2001, Journal of hypertension.